Recent FDA Approvals of Non-Opioid Analgesics: Mechanisms, Indications, and Pivotal Evidence

Recent FDA approvals of non-opioid analgesics: mechanisms, indications, and pivotal evidence

The last several years have produced a small but strategically important set of FDA-approved non-opioid analgesics, spanning a genuinely novel ion-channel mechanism, extended-release local anesthetic combinations for the surgical setting, fixed-dose non-opioid combinations, and a wave of migraine-specific small molecules. The through-line across these programs is a regulatory and clinical push to treat moderate-to-severe pain, especially acute and postsurgical pain, while reducing reliance on opioids. Below is a review of the products, organized by therapeutic setting, with the mechanism of action, approved indication, and the pivotal evidence FDA relied on for each.

Journavx (suzetrigine): first-in-class NaV1.8 inhibitor for acute pain

Journavx (suzetrigine, development code VX-548) is the headline approval in this category. FDA approved the oral NDA on January 30, 2025 for the treatment of moderate to severe acute pain in adults ^86878899. It is a selective inhibitor of the voltage-gated sodium channel subtype NaV1.8, blocking transmission of pain signals to the spinal cord and brain ⁸⁷⁸⁹⁹⁰. Because NaV1.8 is expressed in peripheral pain-sensing neurons rather than the CNS reward pathways engaged by opioids, the mechanism is peripherally acting and non-addictive by design ⁸⁹⁹⁰⁹².

Dosing is a 100 mg oral loading dose taken on an empty stomach, followed by 50 mg every 12 hours for the first several doses and then 50 mg every 24 hours; treatment has not been studied beyond 14 days and should be used for the shortest duration needed ^108116114.

Pivotal evidence came from two randomized, double-blind, placebo- and active-controlled Phase 3 studies in acute postoperative pain, chosen to represent the two classic pain models ^127130121:

• Study 104 (bunionectomy, a bony-pain model): 2:2:1 randomization to suzetrigine, hydrocodone bitartrate/acetaminophen (HB/APAP) 5 mg/325 mg every 6 hours, or placebo, in adults with moderate-to-severe pain and an NPRS score above 4 ^126121127.
• Study 105 (abdominoplasty, a soft-tissue model): near-identical design ^94103121.

The primary endpoint in both was SPID48, the time-weighted sum of pain intensity difference on the 0-to-10 NPRS over 48 hours versus placebo ^9410212664. Suzetrigine met the primary endpoint in both trials: in Study 104, LS mean SPID48 was 99.9 versus 70.6 for placebo (difference 29.3; 95% CI 14.0 to 44.6; p=0.0002) ¹³¹; in Study 105, 118.4 versus 70.1 (difference 48.4; 95% CI 33.6 to 63.1; p<0.0001) ¹³³.

A critical nuance for regulatory readers: FDA's integrated review concluded that suzetrigine did not demonstrate greater pain reduction than the opioid comparator HB/APAP on SPID48 in either study ¹³⁰. The reviewer also flagged that the HB/APAP arm itself failed to separate statistically from placebo on SPID48/SPID24 in these trials, complicating interpretation of the active-control comparison ¹²⁵. The approval therefore rested on superiority to placebo rather than superiority to the opioid comparator.

The most common adverse reactions (more frequent than placebo) were pruritus, muscle spasms, increased creatine phosphokinase, and rash ¹¹⁴¹¹⁶. Strong CYP3A inhibitors are contraindicated, and moderate CYP3A inhibitors require a dose reduction because they raise suzetrigine and active-metabolite exposure; grapefruit should be avoided, use in severe hepatic impairment is not recommended, and suzetrigine is itself a CYP3A inducer that can lower exposure of sensitive substrates ^{108110112114116123}.

Postsurgical non-opioid products: Zynrelef and Combogesic IV

Zynrelef (bupivacaine/meloxicam, HTX-011) was approved May 12, 2021 as an extended-release solution for soft-tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours; the initial procedures were bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty, later expanded to additional foot/ankle, open abdominal, and lower-extremity total-joint procedures ³⁷⁴⁴⁵⁰. It pairs an amide local anesthetic (bupivacaine, which blocks nerve-impulse conduction) with an NSAID (meloxicam, a COX-1/COX-2 inhibitor that lowers inflammatory prostaglandins), formulated for prolonged local release ³³⁴⁸⁵⁰.

The pivotal program was two Phase 3, randomized, double-blind, saline-placebo- and active-controlled studies: Study 301 (bunionectomy) and Study 302 (open inguinal herniorrhaphy with mesh) ^139141143. The primary endpoint was the mean area under the curve of NRS pain intensity with activity through 72 hours (AUC0-72) versus saline placebo, with hierarchical testing of key secondary endpoints including AUC versus bupivacaine HCl alone, total 72-hour opioid consumption, and the proportion of patients opioid-free ^139141151152. In both studies HTX-011 produced statistically significantly lower pain intensity than both saline placebo and bupivacaine alone and reduced opioid use, with more patients opioid-free through 72 hours ^138141146157. For example, in Study 301 the opioid-free proportion was 28.7% for HTX-011 versus 2.0% placebo and 11.0% bupivacaine; in Study 302 it was 51.2% versus 22.0% placebo and 40.1% bupivacaine ¹⁴⁶. The demonstrated separation from bupivacaine alone was the key differentiator supporting the combination.

Combogesic IV (acetaminophen/ibuprofen) was approved in 2023 (Drugs@FDA decision date October 17, 2023) as an intravenous fixed-dose combination given as a 15-minute infusion ^170177161. It combines two analgesics with different mechanisms of action and is indicated in adults, where the IV route is clinically necessary, for relief of mild-to-moderate pain and management of moderate-to-severe pain as an adjunct to opioids, for short-term use of five days or less ^162171163. Efficacy was supported by a single pivotal Phase 3 trial, AFT-MXIV-07, a placebo-controlled, randomized, double-blind bunionectomy study comparing the combination against acetaminophen alone, ibuprofen alone, and placebo; the primary endpoint SPID48 showed statistically significant pain relief versus all three comparators ^162173161. A separate open-label single-arm study (AFT-MXIV-11) provided prolonged-exposure safety data ¹⁶². An oral acetaminophen/ibuprofen fixed combination (Combogesic) was also approved for short-term management of mild-to-moderate acute pain in adults, with supporting data in postoperative dental pain ⁶⁵⁷⁶.

Acute migraine: non-opioid small molecules

Migraine is a headache-pain indication where non-opioid, migraine-specific agents have largely displaced older approaches. Two mechanistic classes reached the market in this window.

CGRP receptor antagonists (gepants). These oral or intranasal small molecules block the calcitonin gene-related peptide receptor and are indicated for the acute treatment of migraine with or without aura in adults. All were evaluated against the modern co-primary endpoints of pain freedom at 2 hours and freedom from the most bothersome symptom (MBS) at 2 hours versus placebo:

• Ubrelvy (ubrogepant), approved December 23, 2019, an oral CGRP receptor antagonist studied in UBR-MD-01 and UBR-MD-02, both positive on the 2-hour co-primary endpoints ^91423182.
• Nurtec ODT (rimegepant), approved February 27, 2020, an oral (orally disintegrating) CGRP receptor antagonist; the 75 mg dose was superior to placebo on 2-hour pain freedom and MBS freedom across a program of nearly identically designed studies (e.g., ODT study BHV3000-303: 21.2% vs 10.9% pain freedom; 35.1% vs 26.8% MBS freedom) ^51317187.
• Zavzpret (zavegepant), approved March 9, 2023, the first intranasal CGRP receptor antagonist; two adequate and well-controlled studies showed the 10 mg dose superior to placebo on both 2-hour endpoints, while 5 mg was not effective ^21121191192.

5-HT1F receptor agonist (ditan). Reyvow (lasmiditan) was approved October 11, 2019 for the acute treatment of migraine with or without aura in adults ^198206207. It is a selective, centrally penetrant 5-HT1F agonist that relieves migraine by reducing neuropeptide release and inhibiting trigeminal pain pathways without the vasoconstriction associated with triptans ²⁰²²⁰⁷. Two adequate and well-controlled pivotal studies showed efficacy on 2-hour pain freedom and MBS freedom across the tested doses; the trials did not establish efficacy of a second dose for recurrence, so labeling recommends a single dose in 24 hours ^198201200.

What the evidence base has in common

Several themes recur across these approvals and are worth noting for anyone benchmarking a non-opioid pain program:

• Standardized acute-pain models and endpoints. The postoperative programs (Journavx, Zynrelef, Combogesic IV) leaned on bunionectomy (bony pain) and soft-tissue models (abdominoplasty, herniorrhaphy) with time-weighted summed pain-intensity-difference endpoints (SPID48) or 72-hour pain-intensity AUC ^126121139162. The migraine programs converged on the 2-hour pain-freedom / MBS-freedom co-primary endpoints ^18218711198.
• Superiority to placebo, not necessarily to active comparators. Journavx illustrates the point sharply: it met its placebo-controlled primary endpoint but did not beat the opioid comparator, and FDA documented that limitation explicitly ¹³⁰¹²⁵.
• Combination products earn their approval by beating their own components. Zynrelef and Combogesic IV both had to demonstrate separation from the individual actives (bupivacaine alone; acetaminophen and ibuprofen alone), not just placebo ^141146162173.

For deeper follow-ups, a reader could ask Rhizome to pull the full FDA clinical and statistical review narratives for any single product, compare the Journavx benefit-risk discussion against the opioid comparator data in detail, or map the Orange Book exclusivity and patent positions now protecting these molecules.